Alexander B. Olawaiye, MD, shares how relacorilant’s recent approval might change the treatment landscape for ovarian cancer.
A prospective survey study presented at the 2026 ASCO Annual Meeting highlighted the heterogeneity of patient experiences ...
Amram Kahn, MD, shares strategies for reconciling disparate clinical recommendations to optimize medication regimens for ...
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be prescribed to people with heart failure, chronic kidney disease, ...
To support physicians facing escalating economic pressures on independent practice, the AMA on June 11, 2026, launched an affinity program with Panacea Financial, a financial technology platform built ...
As fireworks injuries and fires surge around July 4th, officials urge safer celebrations and greater public awareness nationwide.
"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.
Physician's Weekly Editor VICTORY trial data challenge the use of high-dose vitamin C in severe burn care due to lack of efficacy and safety concerns.
Founder of Injexi. MS Biotechnology, Drexel University College of Medicine. Research experience in lipid nanoparticle-based precision therapeutics for traumatic brain injury and translational TBI ...
In biotech, failure fuels progress. In medicine, it signals harm. The startup world is built on a simple, almost intuitive principle: Fail fast. Move quickly, test aggressively, learn from what ...
Polypharmacy, the concurrent use of multiple medications by a single patient, has become one of the most significant challenges in modern healthcare. While often necessary for managing multiple ...
Peanut allergy, which affects 2% to 3% of children in high‑income countries, has historically been managed with strict avoidance; however, both oral immunotherapy (OIT) and probiotic peanut oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results